Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 14;11(15):5570-5578.
doi: 10.18632/aging.102138. Epub 2019 Aug 14.

Effects of inflammatory responses, apoptosis, and STAT3/NF-κB- and Nrf2-mediated oxidative stress on benign prostatic hyperplasia induced by a high-fat diet

Affiliations

Effects of inflammatory responses, apoptosis, and STAT3/NF-κB- and Nrf2-mediated oxidative stress on benign prostatic hyperplasia induced by a high-fat diet

Yongzhi Li et al. Aging (Albany NY). .

Abstract

This study determined whether or not benign prostatic hyperplasia (BPH) induced by a high-fat diet (HFD) is involved in inflammatory responses, apoptosis, and the signal transducer and activator of transcription (STAT3)/nuclear factor-kappa B (NF-κB)- and nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated oxidative stress pathways. Forty rats were divided into four groups: control; HFD; testosterone; and HFD+testosterone. Hematoxylin and eosin (HE) staining was used to assess histologic changes. An enzyme-linked immunosorbent assay and Western blot analysis were used to detect levels of related proteins. Compared with the control group, the prostate levels of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), malondialdehyde (MDA), transforming growth factor-β1 (TGF-β1), and monocyte chemotactic protein-1 (MCP-1) were significantly increased, while the levels of glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and superoxide dismutase (SOD) were decreased. The TNF-κB, Bcl-2, and caspase-3 levels were increased, while the Bax level was markedly decreased. The cytoplasmic expression of STAT3 and NF-κB was increased, while the nuclear expression of Nrf2 was markedly decreased compared with the control group. In summary, our results demonstrated that a long-term HFD might cause changes in inflammatory responses, apoptosis, and oxidative stress, thus contributing to prostatic hyperplasia. The underlying mechanisms might be related to the STAT3/NF-κB- and Nrf2-mediated oxidative stress pathway.

Keywords: apoptosis; benign prostatic hyperplasia; high-fat diet; inflammatory responses; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Histologic changes in rat prostate (HE stain, ×40). (A) Control group; (B) HFD group; (C) Testosterone group; (D) HFD+testosterone group.
Figure 2
Figure 2
Effects of a long-term HFD on prostatic COX-2, iNOS, TNF-α, IL-6, TGF-β1, MCP-1, MDA, SOD, GSH-Px, GR, and GSH (AK) levels by ELISA. Results are representative of three independent experiments. ##p<0.01 and #p<0.05, compared with the control group; *p<0.05 compared with the testosterone group.
Figure 3
Figure 3
Effects of a long-term HFD on the expression of NF-κB, Bcl-2, Bax, caspase-3, STAT3, NF-κB, p65, and Nrf2 protein. ##p<0.01 and #p<0.05 compared with the control group; *p<0.05 compared with the testosterone group.

Similar articles

Cited by

References

    1. Sharma M, Chadha R, Dhingra N. Phytotherapeutic Agents for Benign Prostatic Hyperplasia: an Overview. Mini Rev Med Chem. 2017; 17:1346–63. 10.2174/1389557516666160621103817 - DOI - PubMed
    1. Napal Lecumberri S, Insausti Gorbea I, Sáez de Ocáriz García A, Solchaga Álvarez S, Cebrián Lostal JL, Monreal Beortegui R, Giral Villalta PJ, Urtasun Grijalba F. Prostatic artery embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: protocol for a non-inferiority clinical trial. Res Rep Urol. 2018; 10:17–22. 10.2147/RRU.S139086 - DOI - PMC - PubMed
    1. La Vignera S, Condorelli RA, Russo GI, Morgia G, Calogero AE. Endocrine control of benign prostatic hyperplasia. Andrology. 2016; 4:404–11. 10.1111/andr.12186 - DOI - PubMed
    1. Aaron L, Franco OE, Hayward SW. Review of Prostate Anatomy and Embryology and the Etiology of Benign Prostatic Hyperplasia. Urol Clin North Am. 2016; 43:279–88. 10.1016/j.ucl.2016.04.012 - DOI - PMC - PubMed
    1. Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest. 2014; 37:313–22. 10.1007/s40618-014-0051-3 - DOI - PubMed

Publication types